• Publications
  • Influence
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
TLDR
This new adenocarcinoma classification is needed to provide uniform terminology and diagnostic criteria, especially for bronchioloalveolar carcinoma (BAC), the overall approach to small nonresection cancer specimens, and for multidisciplinary strategic management of tissue for molecular and immunohistochemical studies. Expand
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.
TLDR
This is the first prospective phase III study in NSCLC to show survival differences based on histologic type and cisplatin/pemetrexed provides similar efficacy with better tolerability and more convenient administration than cis platin/gemcitabine. Expand
Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.
TLDR
Postoperative cisplatin-based chemotherapy significantly improves survival in patients with non-small-cell lung cancer (NSCLC). Expand
Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.
TLDR
Denosumab was noninferior (trending to superiority) to ZA in preventing or delaying first on-study SRE in patients with advanced cancer metastatic to bone or myeloma and represents a potential novel treatment option with the convenience of subcutaneous administration and no requirement for renal monitoring or dose adjustment. Expand
Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.
TLDR
Gefitinib in combination with gemcitabine and cisplatin in chemotherapy-naive patients with advanced NSCLC did not have improved efficacy over gemcitABine and cascplatin alone, and the reasons for this remain obscure and require further preclinical testing. Expand
Lung cancer: current therapies and new targeted treatments
TLDR
Prevention and early detection of lung cancer with an emphasis on lung cancer screening is discussed, and the importance of smoking prevention and cessation is acknowledged. Expand
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.
TLDR
This large, placebo-controlled trial confirmed the favorable gefitinib safety profile observed in phase I and II monotherapy trials and showed no added benefit in survival, time to progression, response rate (TTP), or RR compared with standard chemotherapy alone. Expand
Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.
TLDR
Efficacy end points were not significantly different between experimental and reference arms, although toxicities showed differences, which suggest that chemotherapy in NSCLC has reached a therapeutic plateau. Expand
The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies.
TLDR
It is suggested pemetrexed should not be recommended for the treatment of squamous cell carcinoma, but, because of efficacy and safety advantages, it may be preferable to other agents for treatment of patients with nonsquamous NSCLC. Expand
Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer.
TLDR
This randomized trial failed to prospectively confirm a statistically significant role for adjuvant chemotherapy in completely resected NSCLC and given the poor compliance with the MVP regimen used in this study, future studies should explore more effective treatments. Expand
...
1
2
3
4
5
...